| 4CNI: reference: Discovery and characterization of olokizumab: A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling., Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S, Marshall D, Moore A, Neale H, Lawson A, MAbs. 2014 May 1;6(3):773-81. doi: 10.4161/mabs.28612. Epub 2014 Apr 2. PMID: 24670876 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).